Biotech companies are always searching for new ways to fund the costly and uncertain process of drug development and product launch. Over the past several years, synthetic royalty and drug development financings have become an additional option for fundraising, as traditional equity markets have remained challenging. Covington & Burling’s third
Continue Reading Synthetic Royalty and Drug Development Financings – A Funding Structure Growing in Europe
Julian Wright
Julian Wright is special counsel in the firm’s Finance Practice Group. Working closely with colleagues in the firm’s Private Equity Practice Group, he regularly advises private equity firms and their portfolio companies on a broad range of finance transactions. His practice also encompasses counseling private investment funds, public and private companies, and a range of other firm clients on their financing and other business needs across sectors as diverse as agriculture, food and beverage, life sciences, oil and gas, sports, and technology. Julian’s representative transactions include structuring and negotiating club, syndicated and direct lending facilities, secured and unsecured domestic and cross-border credit financings, asset-based facilities, convertible loans, fund-level financings, project financings, restructurings, and the monetization of pharmaceutical royalty streams.